Legumain Antibody (B-10): sc-166971

Legumain Antibody (B-10) is a mouse monoclonal IgG1 antibody that detects Legumain in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Legumain, also known as LGMN, AEP (asparaginyl endopeptidase), or PRSC1, is a 433 amino acid protein that plays a crucial role as a cysteine protease, specifically catalyzing the hydrolysis of asparaginyl and aspartyl bonds. This enzymatic activity is particularly important for processing proteins within the lysosomal/endosomal system, where Legumain is involved in presenting bacterial antigens via MHC class II molecules, a key process for effective immune response. Legumain is predominantly localized in lysosomes and expressed in various tissues, with notably high levels in placenta, heart, and kidney. Legumain exists in both precursor and fully mature forms, with active enzyme being produced in dendritic cells. Overexpression of Legumain has been linked to solid tumor development, indicating potential roles in carcinogenesis. Multiple isoforms of Legumain arise from alternative splicing, contributing to diverse functional roles in cellular processes. Anti-Legumain antibody (B-10) is an essential tool for researchers investigating Legumain′s implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Legumain Antibody (B-10) References:

1. Effects of legumain as a potential prognostic factor on gastric cancers.  |  Li, N., et al. 2013. Med Oncol. 30: 621. PMID: 23740003
2. Prognostic value of legumain in uveal melanoma.  |  Wu, T., et al. 2016. Mol Med Rep. 13: 2377-84. PMID: 26846877
3. Legumain is activated in macrophages during pancreatitis.  |  Edgington-Mitchell, LE., et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G548-60. PMID: 27514475
4. Legumain acts on neuroinflammatory to affect CUS-induced cognitive impairment.  |  Lian, J., et al. 2019. Behav Brain Res. 376: 112219. PMID: 31509774
5. Relationship between Increased Plasma Levels of Legumain and Properties of Coronary Atherosclerotic Plaque.  |  Deng, Y., et al. 2023. Arq Bras Cardiol. 120: e20230395. PMID: 37909538
6. Tumor-Targeted Fluorescent/Photoacoustic Imaging of Legumain Activity In Vivo.  |  Wang, M., et al. 2023. ACS Sens. 8: 4473-4477. PMID: 37982675
7. Plasma legumain in familial hypercholesterolemia: associations with statin use and cardiovascular risk markers.  |  Gregersen, I., et al. 2024. Scand J Clin Lab Invest. 84: 24-29. PMID: 38319290
8. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers.  |  Gray, ME., et al. 2024. Xenobiotica. 54: 458-468. PMID: 38738708
9. Legumain-deficient macrophages regulate inflammation and lipid metabolism in adipose tissues to protect against diet-induced obesity.  |  Zhang, W., et al. 2024. Mol Cell Endocrinol. 592: 112283. PMID: 38815795
10. SERPINB7 Deficiency Increases Legumain Activity and Impairs the Epidermal Barrier in Nagashima-Type Palmoplantar Keratoderma.  |  Li, S., et al. 2025. J Invest Dermatol. 145: 359-369.e8. PMID: 38909841

The preferred Legumain antibody is Legumain Antibody (B-8): sc-133234.